Cancer mortality in kidney transplant recipients: An Australian and New Zealand population-based cohort study, 1980-2013.
cancer
end-stage kidney disease
kidney transplantation
mortality
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 05 2020
15 05 2020
Historique:
received:
05
05
2019
accepted:
04
07
2019
pubmed:
25
7
2019
medline:
23
9
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
Cancer burden is increasing in kidney transplant recipients, but differences in mortality compared to the general population remain unclear. We sought to compare cancer mortality in paediatric and adult kidney transplant recipients with the general population and describe any differences, by site, age and sex, country and over time. We included kidney transplant recipients from the Australian and New Zealand Dialysis and Transplantation Registry, 1980-2013. Date of death and underlying cause of death were ascertained by data-linkage and classified using ICD10AM codes. Indirect standardisation was used to estimate standardised mortality ratios (SMR). There were 5,284 deaths in 17,628 kidney transplant recipients over 175,084 person-years of observation, including 1,061 (20%) cancer deaths. Relative cancer mortality was higher than the general population for all-site (SMR 2.9, 95% CI 2.7-3.1) cancer and highest for nonmelanoma skin cancer (SMR 50.9, 95% CI 43.5-59.6) and lymphoma (SMR 42.2, 95% CI 35.3-50.5). Relative cancer mortality decreased with increasing age in men (p < 0.001) and women (p = 0.001) but never reached parity with the general population. Relative mortality did not change with age for skin and lip, or colorectal cancers (p-value >0.1). Only relative colorectal cancer mortality increased over time (p = 0.002). Our study shows cancer mortality in kidney transplant recipients was higher than expected in the general population. The magnitude of excess mortality varied by cancer site, age and sex. Further evidence is needed to identify whether this variation is due to differences at diagnosis or access and effectiveness of cancer treatments in this population.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2703-2711Informations de copyright
© 2019 UICC.
Références
Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010;21:852-8.
Australian Institute of Health and Welfare. Cancer in Australia 2017. Canberra, Australia: AIHW, 2017.
Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada. J Am Med Assoc Oncol 2016;2:463-9.
ANZDATA Registry. Chapter 3: Mortality in End Stage Kidney Disease. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry, 2018.
Pilmore H, Dent H, Chang S, et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010;89:851-7.
Lam NN, Kim SJ, Knoll GA, et al. The risk of cardiovascular disease is not increasing over time despite aging and higher comorbidity burden of kidney transplant recipients. Transplantation 2017;101:588-96.
Kiberd BA, Rose C, Gill JS. Cancer mortality in kidney transplantation. Am J Transplant 2009;9:1868-75.
Au EH, Chapman JR, Craig JC, et al. Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant. J Am Soc Nephrol 2019; https://doi.org/10.1681/10.1681/ASN.2018090906.
Sypek MP, Dansie KB, Clayton P, et al. Comparison of cause of death between anzdata and the australian national death index. Nephrology (Carlton) 2018;24:322-9.
Boyd JH, Randall SM, Ferrante AM. Application of privacy-preserving techniques in operational record linkage centres. In: Gkoulalas-Divanis A, Loukides G, eds Medical data privacy Handbook. Cham: Springer International Publishing, 2015. 267-87.
Lawrence G, Dinh I, Taylor L. The Centre for Health Record Linkage: a new resource for health services research and evaluation. Health Inform Manage J 2008;37:60-2.
Australian Consortium for Classification Development. The international statistical classification of diseases and related health problems, tenth revision, Australian modification (ICD-10-AM/ACHI/ACS), 9th edn. Darlinghurst, NSW, Australia: Independent Hospital Pricing Authority, 2015.
Australian Consortium for Classification Development. ICD-10-AM/ACHI/ACS, vol. 2019. Darlinghurst, NSW, Australia: Independent Hospital Pricing Authority, 2019.
Roberts RF, Innes KC, Walker SM. Introducing ICD-10-AM in Australian hospitals. Med J Aust 1998;169 Suppl:S32-5.
Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
Farewell VT. Statistical methods for individual-level data in cohort mortality studies of rheumatic diseases. Communications in Statistics - Theory and Methods 2009;38:3472-87.
Carroll RP, Ramsay HM, Fryer AA, et al. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 2003;41:676-83.
Iannacone MR, Sinnya S, Pandeya N, et al. Prevalence of skin cancer and related skin Tumors in high-risk kidney and liver transplant recipients in Queensland, Australia. J Invest Dermatol 2016;136:1382-6.
Vajdic CM, Chong AH, Kelly PJ, et al. Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study. Am J Transplant 2014;14:1368-75.
D'Arcy ME, Coghill AE, Lynch CF, et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer 2019;125:933-42.
Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014;349:g6679.
ANZDATA Registry. Chapter 7: Transplantation. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry, 2018.
Krisl JC, Doan VP. Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients. Am J Transplant 2017;17:1974-91.
Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006;82:375-81.